Milestone Pharmaceuticals: Potential NDA Submission Of Etripamil Catalyst Set For Mid-2023

Terry Chrisomalis
Investing Group Leader

Summary

  • Etripamil succeeded in phase 3 RAPID study, Milestone in talks with FDA to possibly file an NDA for this drug in treating PSVT patients by mid-2023.
  • It is said that there are about 2 million PSVT patients in the United States currently.
  • Etripamil is being explored in an ongoing phase 2 proof of concept study in atrial fibrillation; Successful results could allow it to target a larger market.
  • Milestone Pharmaceuticals had $86.2 million in cash as of June 30, 2022; It believes it has enough to fund its operations until the 2nd half of 2022, however, I believe it will likely raise cash again in 1st half of 2023.
  • This idea was discussed in more depth with members of my private investing community, Biotech Analysis Central. Learn More »

biochemical research scientist working with a microscope for the virus,Doctor man write a history of the experimental results in a , laboratory glassware containing chemical liquid for design.

Bussarin Rinchumrus/iStock via Getty Images

Milestone Pharmaceuticals (NASDAQ:MIST) is a great speculative biotech play to look into. It is because one indication in the pipeline has been somewhat de-risked. This involves the use of a nasal spray drug known

This article is published by Terry Chrisomalis, who runs the >Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.52K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About MIST Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on MIST

Related Stocks

SymbolLast Price% Chg
MIST
--
Compare

Trending Analysis

Trending News